TCGA-CN-6016-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.670
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.450
- COAGULATION+0.420
- NOTCH_SIGNALING+0.410
- APICAL_JUNCTION+0.380
- UV_RESPONSE_DN+0.380
- HEDGEHOG_SIGNALING+0.370
- TGF_BETA_SIGNALING+0.330
- WNT_BETA_CATENIN_SIGNALING+0.310
Top 10 suppressed
- E2F_TARGETS-0.750
- MYC_TARGETS_V1-0.700
- MYC_TARGETS_V2-0.680
- G2M_CHECKPOINT-0.660
- MTORC1_SIGNALING-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.430
- DNA_REPAIR-0.410
- OXIDATIVE_PHOSPHORYLATION-0.390
- FATTY_ACID_METABOLISM-0.210
- CHOLESTEROL_HOMEOSTASIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.930 |
| 2 | SRR26320070 | — | — | 0.924 |
| 3 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.922 |
| 4 | SRR8518128 | — | A | 0.917 |
| 5 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.914 |
| 6 | SRR35579845 | — | A | 0.908 |
| 7 | SRR12475153 | — | — | 0.907 |
| 8 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.905 |
| 9 | SRR5088925 | — | — | 0.905 |
| 10 | TCGA-69-7763-01A-11R-2170-07 | — | cohortA2 | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.670 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |